CT83 is recognized by autologous cytotoxic T cells.7 Recently, Stevanović et al reported that T-cell receptors (TCRs) recognized that human leukocyte antigen (HLA)-A*01:01 presented epitope CT8352-60 from human papillomavirus (HPV)+ cervical cancer patient-mediated complete cancer regression for 46 months.8 The National Institutes of Health of the USA conducted phase I clinical trials for CT83-specific TCR. Here, CT83 is linked to cancer.